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Abstract Congenital disorders of glycosylation (CDG) are
a group of clinically heterogeneous inborn errors of
metabolism. At present, treatment is available for only
one CDG, but potential treatments for the other CDG are on
the horizon. It will be vitally important in clinical trials of
such agents to have a clear understanding of both the
natural history of CDG and the corresponding burden of
disability suffered by patients. To date, no multicentre
studies have attempted to document the natural history of
CDG. This is in part due to the lack of a reliable assessment
tool to score CDG’s diverse clinical spectrum. Based on our
earlier experience evaluating disease progression in disor-
ders of oxidative phosphorylation, we developed a practical
and semi-quantitative rating scale for children with CDG.
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DOI 10.1007/s10545-011-9325-5The Nijmegen Paediatric CDG Rating Scale (NPCRS) has
been validated in 12 children, offering a tool to objectively
monitor disease progression. We undertook a successful
trial of the NPCRS with a collaboration of nine experienced
physicians, using video records of physical and neurolog-
ical examination of patients. The use of NPCRS can
facilitate both longitudinal and natural history studies that
will be essential for future interventions.
Introduction
Since the first report of patients diagnosed with congenital
disorder of glycosylation (CDG) in 1980 (Jaeken et al.
1980), a large number of diverse CDG has been reported.
CDG are multisystem disorders with highly variable
phenotypes and consequently the clinical spectrum associ-
ated continues to expand. Almost any organ system can be
affected in CDG, though the expression and severity of
signs and symptoms can differ widely (Grünewald et al.
2009; Morava et al. 2009).
Due to the high variability in the phenotype, CDG can
mimic other diseases such as mitochondrial disorders
(Briones et al. 2001; Chi et al. 2010; Morava et al. 2006).
Prediction of disease prognosis and assessment of potential
therapeutic interventions depend on a comprehensive
understanding of the natural history of a disease. To date,
no multicentre study has attempted to prospectively
document the natural history of CDG. This is in part due
to the lack of a reliable assessment tool to score the diverse
clinical spectrum. Several tools are available aimed at specific
aspects of progressive diseases (WeeFIM for functional
independence,PEDIandICFsurveysfordisability,orPedSQL
for quality of life), not however including multisystem aspects
of the disease. Based on our earlier experience of evaluating
disease progression in disorders of oxidative phosphorylation,
we developed a practical and semi-quantitative rating scale for
children with CDG .
A novel rating scale was developed for use in patients
with CDG, to be able to monitor the natural history of CDG
and the corresponding burden of disability suffered by
patients. The overlapping clinical spectrum of CDG and
mitochondrial diseases allowed adaptation of the mitochon-
drial disease rating scale, which has already been validated
and successfully used in three metabolic paediatric centres
(Newcastle, Nijmegen and Rome) (Phoenix et al. 2006).
The Nijmegen Paediatric CDG Rating Scale (NPCRS) has
been developed to offer a tool to objectively follow the
clinical disease progression. The score avoids the diagnostic
aspects and is designed to evaluate easily recognizable clinical
signs, assessable by clinicalexamination,that occur frequently
in CDG. The use of NPCRS will facilitate longitudinal natural
history studies and will also be helpful in assessing the impact
of future therapeutic interventions.
Methods
Development of NPCRS
The Nijmegen Paediatric CDG Rating Scale (NPCRS)
comprises a domain structure identical to the Newcastle
Paediatric Mitochondrial Disease Scale (NPMDS), which
has already been successfully validated (Phoenix et al.
2006). Like NPMDS, the NPCRS is based around three
domains, with each domain containing specific items
relevant to the assessment of CDG patients. The three
domains are as follows: Section I (Current Function) is a
domain consisting of five questions regarding five general
functions (vision, hearing, communication, feeding and
mobility); Section II (System Specific Involvement)
includes questions directly assessing CNS, blood, gastroin-
testinal, endocrine, respiratory, cardiovascular, renal and
liver function over the preceding 6 months; Section III
(Current Clinical Assessment) includes questions related to
status. For each item, there are four possible responses
reflecting normal (0), mild (1), moderate (2) and severe (3)
impairment, with one exception in the form of a flow chart
to assess developmental progress for which a score of 0–7
is possible (see Fig. 1 in the Electronic Supplementary
Material). The NPCRS is subdivided into three age ranges,
according to developmental phases, including infancy
and early childhood (0–24 months), middle childhood
(2–11 years) and adolescence (12–18 years).
Patients
We included 12 patients (mean age 8.7 years, SD: 5.6) who
were regularly followed in our clinical centre. Patients’
parents or guardians provided informed consent for partic-
ipation. Subsequently we collected biochemical and genetic
information of these patients, and the findings are shown in
Table 1.
Each patient was examined independently by four
different investigators, on the same day in the same
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investigators rated the patients current clinical status by
performing a physical examination.
Collaborative trial
We further trialed the use of the NPCRS with the
collaboration of nine experienced physicians (European
Metabolic Group conference, Lissabon, 2010). Clinical
history, detailed biochemical information and video records
of the physical examination of two patients with SRD5A3-
CDG (Morava et al. 2010b) demonstrated neurological
involvement (mental retardation, hypotonia, ataxia, dystonia,
and visual loss) but no internal organ involvement. A 15 min
video of the clinical presentation and neurological examina-
tion was reviewed independently after which the participants
were allowed to request additional information, as would
occur during a clinical visit. The age-appropriate version of
NPCRS was used to assess the disease severity in both
patients and the results discussed at the workshop.
Statistics, validation/inter-rater validation
The Kappa test of agreement was used for the measure of
agreement (excess of agreement on categorical data, such as
mild, moderate and severe, is expected owing to chance and
sample size). This was calculated with the observed agree-
ment (ObsA) and the agreement expected by chance (ExpA)
using the following formula: [ObsA − ExpA/1 − ExpA ].
Kappa scores were classified as follows: <0.20 (poor),
0.21–0.40 (fair), 0.41–0.60 (moderate), 0.61–0.80 (good)
and 0.81–1.00 (very good).
Results
Development of the NPCRS
We included only the most common symptoms of CDG
patients in our rating scale corresponding with the literature.
We excluded rare and unique symptoms due to their lack of
discriminatory power of ‘severity’.W eh a v em a d et h e
assumption that in performing a detailed examination of all
12 patients we have not missed any clinical features. We
found application of the scale to be straightforward, taking
approximately 15 min for each patient. Parents and patients
(where possible) found the questions to be clear, and the
investigators did not encounter any particular difficulties in
applying the rating scale to patients.
Patients
Our patient group consisted of five male and seven female
patients ranging from 8 months to 19 years of age. There
was a great diversity in the phenotypic spectrum of the
different patients (see Table 1). Some of the patients have
Table 1 Clinical characteristics, biochemical and genetic data on patients 1–12
Patient (M/F) Age (years) Clinical features Diagnosis Mutations
1 M (Drijvers et al. 2010) 0.8 Psychomotor retardation, failure to thrive,
protein-losing enteropathy, epilepsy
ALG6-CDG p.A333V (c.998 C>T); del
exon 3 (c.257+5 G>A)
2 F 1 Psychomotor retardation, failure to
thrive, hypoglycemia, ataxia
PMM2-CDG hom. p.F119L (c.357 C>A)
3 F (Morava et al. 2010a) 5 Glaucoma, psychomotor retardation, abnormal
liverfunction, hypotonia, inverted nipples
SRD5A3-CDG p.S10x (c.29 C>A)
4 F (Morava et al. 2008) 10 Cutis laxa, failure to thrive, psychomotor
retardation, myopathy
ATP6V0A2-CDG hom. p.R63x (c.187 C>T)
5 F (Morava et al. 2009) 11 Psychomotor retardation, failure to thrive,
diarrhea, CMP, ataxia, hypotonia
PMM2-CDG p.R141H (c.422 G>A);
p.F119 L (c.357 C>A)
6 M 5 Positive family history,
elevated transaminases,
cholestasis
CDG-IIx Unknown
7 F 8 Liver failure, psychomotor retardation,
clotting abnormalities
CDG-IIx Unknown
8 F 3 Strabismus, hypotonia,
psychomotor retardation
PMM2-CDG p.F119L (c.357 C>A);
p.E151G (c.452A>G)
9 M 18 Delayed motor development CDG-Ix Unknown
10 M 16 Short stature, diarrhoea, hypoglycemia CDG-Ix Unknown
11 M 15 Psychomotor retardation, ataxia PMM2-CDG p.R123G (c.324 G>A);
p.R162W (c.484 T>C)
12 F (Hutchagowder 2009) 11 Cutis laxa, growth delay,
psychomotor retardation
ATP6V0A2-CDG p.P405L (c.31908 C>T);
p.R5101 (c.32579 G>T)
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Inter-rater variation
The total scores assigned by each clinician to each of the 12
patientsareshowninTable1 in the Electronic Supplementary
Material. These scores are used to scale patients into a mild
(0–14), moderate (15–25) and severe ( >26) category. There
was very little inter-rater variation regarding the categories
into which the nine experienced clinicians placed the patients,
based on video observation (see domain III in Table 2 in the
Electronic Supplementary Material). All inter-rater com-
parisons were good or very good. In domains I and II there
were no differences between the rates (Kappa value very
good),andindomainIIIthe Kappa valueswereeithergoodor
very good. There was no significant inter-rater variation and
no significant difference regarding the final score.
Discussion
Most of the CDG types commonly present with a severe
clinical phenotype in the first years of life, affecting
multiple organ systems including the central nervous
system. Those who survive this crucial period will stabilise
and show a relatively steady clinical picture by puberty
(Truin et al. 2008; Morava et al. 2008; Cantagrel et al.
2010; Drijvers et al. 2010). One of the most important
aspects of CDG relates to how the disease will affect the
patients and their families in the future. We have been
unable to accurately answer questions regarding prognosis
due to lack of a comprehensive and effective tool to
objectively document the natural history of the disease.
A similar problem was faced by clinicians managing
patients diagnosed with mitochondrial disease, a group that
sharesmanyclinicalfeatureswithCDGpatients.Basedonour
positiveexperienceofusingtherecentlydevelopedNewcastle
Paediatric Mitochondrial Disease Scale (NPMDS, Newcastle,
RomeandNijmegen)inregularclinicalpractice(Moravaetal.
2010a; Koene et al. 2009), we decided to adapt this existing
scale and to validate it in this group of CDG patients.
Therefore, we have collaborated with multiple experienced
clinicians who regularly follow patients with CDG.
One of the major challenges in designing a scale for
CDG patients has been addressing the severity of clinical
features, especially neurological symptoms. Another aspect
is the need to be comprehensive, e.g., many of the clinical
features are either not apparent at diagnosis or are found in
only a minority of patients with that particular type of
disorder. A good example is sensorineural deafness, a very
rare symptom, also difficult to assess in the clinical
outpatient setting and follow progression based on physical
examination in CDG patients (Jaeken et al. 2009).
We additionally reviewed all clinical features of the
patients included in the validation process, and we have not
found any clinical symptoms not included on our clinical
scale. Although our patient cohort was small, their
phenotype was representative for the various types of
CDG. We concluded that the scale is a comprehensive tool
for assessing the disease progression in CDG patients. In
addition to being comprehensive the scale had to be easy
and rapid to use and outpatient clinic–friendly.
Similar to the original NPMDS (Phoenix et al. 2006), the
NPCRS has three key domains which comprise key
questions relating to functional ability. These clinical
criteria are sometimes difficult to define without performing
additional studies (objective measurements of strength,
EMG, nerve conduction studies), especially in the case of
a mild to moderate myopathy or neuropathy. This problem
was also encountered during the validation and use of the
mitochondrial disease scale.
The NPCRS is designed to be applied at the outpatient
visits each 6 months or at least annually throughout the
follow-up period for individual CDG patients. During this
period patients may be assessed by a number of different
paediatricians and therefore the consistency of the scoring
system is very important. In the current validation process we
found no substantial inter-rater variability, but a very good
level of inter-rater agreement in our relatively small, but
phenotypically heterogeneous, cohort of paediatric patients
with CDG (Morava et al. 2008; Hucthagowder et al. 2009).
Our collaborative study showed no significant inter-rater
variability and no differences between the total scores
recorded, further demonstrating the reliability of the CDG
ratingscale.Based onthose findingswerecommend applying
the NPCRS both to facilitate disease severity assessment and
to study longitudinal natural history. In addition, we believe
that the NPCRS will be an important tool in assessing the
clinical impact of future therapeutic interventions.
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